No quarterly revenue total was found in VAXCYTE, INC.'s SEC filings.
Vaxcyte, Inc. (PCVX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$227.4 million. As of Sep 30, 2026 it held $2.3 billion in cash and investments and $221.8 million in total debt.
Revenue
—
Net income
$-297.06M
-39.6% vs year-ago quarter
Operating cash flow
$-224.08M
-56.4% vs year-ago quarter
Free cash flow
$-227.42M
-54.6% vs year-ago quarter
EPS
$-1.99
-27.6% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
158.30M
+20.9% vs year-ago quarter
Net cash
$2.04B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PCVX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1649094
- Former names
- SutroVax, Inc. (until Apr 3, 2020)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$308.3M | -$302.8M | -$345.9M | -$274.3M | -$242.4M |
| Net income | -$297.1M | -$284.3M | -$320.6M | -$246.5M | -$212.8M |
| Diluted EPS | -$1.99 | -$1.97 | -$2.30 | -$1.81 | -$1.56 |
| Operating cash flow | -$224.1M | -$232.5M | -$280.6M | -$224.8M | -$143.3M |
| Free cash flow | -$227.4M | -$236.8M | -$282.7M | -$227.5M | -$147.1M |
| Total assets | $3.0B | $3.1B | $3.3B | $3.0B | $3.2B |
| Total liabilities | $499.9M | $380.2M | $352.3M | $317.2M | $278.7M |
| Stockholders' equity | $2.5B | $2.8B | $3.0B | $2.7B | $2.9B |
| Cash and investments | $2.3B | $2.5B | $2.7B | $2.4B | $2.7B |
| Total debt | $221.8M | $115.4M | $116.3M | $117.6M | $84.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 3, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 767 Vaxcyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.